<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01716026</url>
  </required_header>
  <id_info>
    <org_study_id>IOBA-04-2012</org_study_id>
    <nct_id>NCT01716026</nct_id>
  </id_info>
  <brief_title>Initial Treatment With Bevacizumab in Choroidal Neovascularization Associated to High Myopia</brief_title>
  <acronym>BENEMCOR</acronym>
  <official_title>Establishment of the Initial Protocol With Intravitreal Bevacizumab for the Treatment of Choroidal Neovascularization Associated With High Myopia:3 vs 1.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto Universitario de Oftalmobiología Aplicada</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Instituto Universitario de Oftalmobiología Aplicada</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this protocol is to determine wether the initial protocol in the treatment of
      subfoveal choroidal neovascularization associated to High Myopia with bevacizumab
      intravitreal injections is more effective when using 3 doses vs using 1 single dose in the
      load period
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>October 2012</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Early Treatment Diabetic Retinopathy Study (ETDRS) Best corrected visual acuity</measure>
    <time_frame>1 Year</time_frame>
    <description>Differences in best corrected visual acuity in the exit visit compared to the one obtained at screening visit</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Retinal thickness</measure>
    <time_frame>1 Year</time_frame>
    <description>Retinal thickness assessed by Spectral Domain Optical Coherence Tomography</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of total injections during study</measure>
    <time_frame>1 Year</time_frame>
    <description>Total count of bevacizumab intravitreal injections during the whole study</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">110</enrollment>
  <condition>Choroidal Subfoveal/Juxtafoveal Neovascularization in High Myopia</condition>
  <arm_group>
    <arm_group_label>3 Month Load with 9 month p.r.n.</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>3 Monthly bevacizumab injections with 9 p.r.n. monthly doses if patient meets the treatment criteria for each monthly visit</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Single Dose Load Phase</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose treatment with bevacizumab, followed by 2 sham injections if conditions are met in the months 2 and 3, and followed with bevacizumab monthly p.r.n. as per protocol</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevazizumab intravitreal injection</intervention_name>
    <description>Intravitreal injection of bevacizumab</description>
    <arm_group_label>3 Month Load with 9 month p.r.n.</arm_group_label>
    <arm_group_label>Single Dose Load Phase</arm_group_label>
    <other_name>Avastin Injection</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Active subfoveal/juxtafoveal choroidal neovascularization in high myopia confirmed by
             Fundus Fluorescein angiography and Optical Coherence Tomography

          -  Best corrected visual acuity loss with less than 6 months of evolution, caused mainly
             by the neovascular lesion (based in investigator´s criteria)

          -  No atrophy or fibrotic component that may prevent visual acuity improvement

          -  Patients previously treated with Photodynamic Therapy are allowed to participate in
             this study

          -  Signed informed consent

          -  Signed data protection consent

          -  Negative pregnancy test in potential childbearing women at screening, with accepted
             contraceptive method during the whole study

        Exclusion Criteria:

          -  Previous vitreous surgery in study eye

          -  Tractional maculopathy or epiretinal membrane found in Optical Coherence Tomography

          -  Media opacities that may prevent correct fundus assessment

          -  Lack of posterior capsule integrity in pseudophakic patients

          -  Patients with great possibilities of not being able to attend to study visits / follow
             visit procedures (investigator´s criteria)

          -  Patients previously treated with intravitreal antiangiogenic injections
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jose Maria Ruiz-Moreno, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Castilla-La Mancha</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHUS - Fundacion IDICHUS</name>
      <address>
        <city>Santiago de Compostela</city>
        <state>La Coruña</state>
        <zip>15706</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica Universitaria de Navarra</name>
      <address>
        <city>Pamplona</city>
        <state>Navarra</state>
        <zip>31080</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario de Albacete</name>
      <address>
        <city>Albacete</city>
        <zip>02006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universitario San Carlos</name>
      <address>
        <city>Madrid</city>
        <zip>28010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Ramón y Cajal</name>
      <address>
        <city>Madrid</city>
        <zip>28031</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Reina Sofia</name>
      <address>
        <city>Murcia</city>
        <zip>30100</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen de Valme</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen de la Macarena</name>
      <address>
        <city>Sevilla</city>
        <zip>41071</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario de Valencia</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IOBA - Instituto Universitario de Oftalmobiologia Aplicada</name>
      <address>
        <city>Valladolid</city>
        <zip>47011</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Rio Hortega</name>
      <address>
        <city>Valladolid</city>
        <zip>47012</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 25, 2012</study_first_submitted>
  <study_first_submitted_qc>October 25, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 29, 2012</study_first_posted>
  <last_update_submitted>March 27, 2017</last_update_submitted>
  <last_update_submitted_qc>March 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>high myopia</keyword>
  <keyword>choroidal neovascularization</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myopia</mesh_term>
    <mesh_term>Neovascularization, Pathologic</mesh_term>
    <mesh_term>Choroidal Neovascularization</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

